Rare Daily Staff

Richard Scheller, a high-profile figure in drug discovery, has joined BridgeBio on the heels of its recent $349 million IPO, as first reported by STAT.

BridgeBio develops medicines for genetic diseases and has built a broad portfolio of candidates through its various subsidiaries.

Scheller, who most recently served as the chief scientific officer at the consumer genetics company 23andMe, will serve as chairman of research and development of BridgeBio. He remains on the 23andMe board.

Scheller joined 23andMe in 2015 as chief scientific officer and head of therapeutics as the company sought to harness its access to genetic data as a starting point for discovering novel therapies. He rose to prominence through his 14 years at Genentech, where he served as executive vice president and head of Genentech research and early development.

Prior to his work in industry, Scheller served as a professor of biological sciences at Stanford University and was a Howard Hughes Medical Institute investigator at the Stanford University School of Medicine.

He is the winner of a 2013 Albert Lasker Basic Medical Research Award, a 2010 Kavli Prize in Neuroscience, and a 1997 US National Academy of Sciences Award in Molecular Biology.

Photo: Richard Scheller, chairman of research and development of BridgeBio

X